Papzimias: Revolutionizing RRP Treatment episode artwork

EPISODE · May 13, 2026 · 1 MIN

Papzimias: Revolutionizing RRP Treatment

from The Daily News Now! Business

Papzimias, the first approved treatment for adults with recurrent respiratory papillomatosis, has made a strong start with $21.6 million in net revenue in its first full quarter. With over 90% payer coverage and positive feedback from doctors, its gaining traction as the new standard. The company expects to reach breakeven by the end of 2026, with redosing trials and a pediatric study underway. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/683388bd8fc6f161

NOW PLAYING

Papzimias: Revolutionizing RRP Treatment

0:00 1:47

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Daily News Now! Business?

This episode is 1 minute long.

When was this The Daily News Now! Business episode published?

This episode was published on May 13, 2026.

What is this episode about?

Papzimias, the first approved treatment for adults with recurrent respiratory papillomatosis, has made a strong start with $21.6 million in net revenue in its first full quarter. With over 90% payer coverage and positive feedback from doctors,...

Can I download this The Daily News Now! Business episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!